Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …
Please refer to Protocol
To determine if overall survival (OS) is improved with proton beam therapy (PBT) treatment as compared to intensity modulated radiation therapy (IMRT) as part of planned protocol treatment for patients with esophageal cancer. To determine if OS with PBT is non-inferior to IMRT as part of planned protocol treatment and …
See Attached Submission Documents See Attached Submission Documents See Attached Submission Documents
Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives)
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in multiple myeloma patients.
This is an umbrella research study is designed to learn more about the safety and effectiveness of AMG 510 in combination with different investigational agents. Eligible subjects include adults with KRAS p.G12C Mutation.
The HER2 regulates cell growth and survival. This study will evaluate a new treatment using a potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with metastatic HER2 positive breast cancer. It is anticipated …
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors. We would like to rely on Advarra as the IRB of record for this study.
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
